select a format

Single User License
USD 2000 INR 130240
Site License
USD 4000 INR 260480
Corporate User License
USD 6000 INR 390720

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Crohns Disease (Regional Enteritis)-Pipeline Review, H1 2017

Crohns Disease (Regional Enteritis)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9074IDB
  • |
  • Pages: 414
  • |
  • March 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Crohn's Disease (Regional Enteritis)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease (Regional Enteritis)-Pipeline Review, H1 2017, provides an overview of the Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline landscape.

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease (Regional Enteritis)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 11, 28, 25, 37, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis) (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Crohn's Disease (Regional Enteritis) (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Crohn's Disease (Regional Enteritis) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis) (Gastrointestinal)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Regional Enteritis) (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

Introduction 6

Crohn's Disease (Regional Enteritis)-Overview 7

Crohn's Disease (Regional Enteritis)-Therapeutics Development 8

Crohn's Disease (Regional Enteritis)-Therapeutics Assessment 26

Crohn's Disease (Regional Enteritis)-Companies Involved in Therapeutics Development 38

Crohn's Disease (Regional Enteritis)-Drug Profiles 79

Crohn's Disease (Regional Enteritis)-Dormant Projects 374

Crohn's Disease (Regional Enteritis)-Discontinued Products 381

Crohn's Disease (Regional Enteritis)-Product Development Milestones 383

Appendix 398

List of Figures

Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by 4D Pharma PLC, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by AB Science SA, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by AbbVie Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Adello Biologics LLC, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Aerpio Therapeutics Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Alfa Wassermann SpA, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Allergan Plc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Alteogen Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Amgen Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by ARA Healthcare Pvt Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Arena Pharmaceuticals Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Astellas Pharma Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Atlantic Bio Sci LLC, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by BioLingus AG, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by BioTherapeutics Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Bristol-Myers Squibb Company, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Calypso Biotech SA, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Celgene Corp, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Cellceutix Corp, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by ChemoCentryx Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by ChironWells GmbH, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by CLL Pharma SA, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Coherus BioSciences Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Commence Bio Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Concenter BioPharma Silkim Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by DBV Technologies SA, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Eisai Co Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Eli Lilly and Company, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Enterome Bioscience SA, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Enzo Biochem Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Ferring International Center SA, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Galapagos NV, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Genentech Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Genor BioPharma Co Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by iCo Therapeutics Inc., H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Iltoo Pharma, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Immune Response BioPharma Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Immune Therapeutics Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Inception Sciences Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Innovent Biologics Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Johnson & Johnson, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Jyant Technologies Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Kang Stem Biotech Co Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by KPI Therapeutics Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Merck & Co Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Merck KGaA, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Mesoblast Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Momenta Pharmaceuticals Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Mycenax Biotech Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by NeuClone Pty Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Novartis AG, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Oncodesign SA, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Panacea Biotec Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Pfenex Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Protagonist Therapeutics Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Protalix BioTherapeutics Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Qu Biologics Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Re-Pharm Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by RedHill Biopharma Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Sandoz International GmbH, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by SATT North SAS, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Second Genome Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Shire Plc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Sigmoid Pharma Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Soligenix Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Stelic Institute & Co Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Sylentis SAU, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Synedgen Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Synlogic Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Tiziana Life Sciences Plc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Trino Therapeutics Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Ventria Bioscience, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Virobay Inc, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Vivelix Pharmaceuticals Ltd, H1 2017

Crohn's Disease (Regional Enteritis)-Pipeline by Xbrane Biopharma AB, H1 2017

Crohn's Disease (Regional Enteritis)-Dormant Projects, H1 2017

Crohn's Disease (Regional Enteritis)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Crohn's Disease (Regional Enteritis)-Dormant Projects, H1 2017 (Contd..2), H1 2017

Crohn's Disease (Regional Enteritis)-Dormant Projects, H1 2017 (Contd..3), H1 2017

Crohn's Disease (Regional Enteritis)-Dormant Projects, H1 2017 (Contd..4), H1 2017

Crohn's Disease (Regional Enteritis)-Dormant Projects, H1 2017 (Contd..5), H1 2017

Crohn's Disease (Regional Enteritis)-Dormant Projects, H1 2017 (Contd..6), H1 2017

Crohn's Disease (Regional Enteritis)-Discontinued Products, H1 2017

Crohn's Disease (Regional Enteritis)-Discontinued Products, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4D Pharma PLC, AB Science SA, AbbVie Inc, Adello Biologics LLC, Aerpio Therapeutics Inc, Alfa Wassermann SpA, Allergan Plc, Alteogen Inc, Amgen Inc, ARA Healthcare Pvt Ltd, Arena Pharmaceuticals Inc, Astellas Pharma Inc, Atlantic Bio Sci LLC, BioLingus AG, BioTherapeutics Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Calypso Biotech SA, Celgene Corp, Cellceutix Corp, ChemoCentryx Inc, ChironWells GmbH, CLL Pharma SA, Coherus BioSciences Inc, Commence Bio Inc, Concenter BioPharma Silkim Ltd, Daiichi Sankyo Company Ltd, DBV Technologies SA, Eisai Co Ltd, Eli Lilly and Company, Enterome Bioscience SA, Enzo Biochem Inc, Ferring International Center SA, Galapagos NV, Genentech Inc, Genor BioPharma Co Ltd, iCo Therapeutics Inc., Iltoo Pharma, Immune Response BioPharma Inc, Immune Therapeutics Inc, Inception Sciences Inc, Innovent Biologics Inc, Johnson & Johnson, Jyant Technologies Inc, Kang Stem Biotech Co Ltd, KPI Therapeutics Inc, Kyorin Pharmaceutical Co Ltd, Merck & Co Inc, Merck KGaA, Mesoblast Ltd, Mitsubishi Tanabe Pharma Corp, Momenta Pharmaceuticals Inc, Mycenax Biotech Inc, NeuClone Pty Ltd, Novartis AG, Oncodesign SA, Panacea Biotec Ltd, Pfenex Inc, Protagonist Therapeutics Inc, Protalix BioTherapeutics Inc, Qu Biologics Inc, Re-Pharm Ltd, RedHill Biopharma Ltd, Reliance Life Sciences Pvt Ltd, Sandoz International GmbH, SATT North SAS, Second Genome Inc, Shire Plc, Sigmoid Pharma Ltd, Soligenix Inc, Stelic Institute & Co Inc, Sylentis SAU, Synedgen Inc, Synlogic Inc, TaiwanJ Pharmaceuticals Co Ltd, Takeda Pharmaceutical Company Ltd, Tiziana Life Sciences Plc, Trino Therapeutics Ltd, Ventria Bioscience, Virobay Inc, Vivelix Pharmaceuticals Ltd, Xbrane Biopharma AB

Crohn's Disease (Regional Enteritis) Therapeutic Products under Development, Key Players in Crohn's Disease (Regional Enteritis) Therapeutics, Crohn's Disease (Regional Enteritis) Pipeline Overview, Crohn's Disease (Regional Enteritis) Pipeline, Crohn's Disease (Regional Enteritis) Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com